Moderna, Inc has received US FDA Fast Track designation for its investigational Zika vaccine based on its messenger RNA (mRNA) technology. The US Food and Drug Administration (FDA) has been granted to mRNA-1893, a vaccine intended to treat Zika currently in Phase I clinical studies. The Fast Track designation is designed to speed up development and review of therapies and vaccines needed to fill an unmet medical need. “Our Zika program is part of Moderna’s broader commitment to improving global…